With indistinguishable endoscopic or histologic features, monogenic inflammatory bowel disease (IBD) and polygenic IBD can be difficult to differentiate and accurately diagnosis via traditional methods.1 Despite having a similar presentation to polygenic IBD, however, monogenic IBD doesn’t typically respond to approved IBD therapies. This results in numerous children undergoing unnecessary invasive procedures and potentially harmful treatments.
Monogenic IBD Test menu
Our genetic IBD panel evaluates for variants in 51 genes with established associations to inherited illnesses that resemble IBD but do not respond to standard treatments. A team of experienced laboratory directors and genetic counselors familiar with the latest literature interpret test results and classify detected variants using American College of Medical Genetics and Genomics/Association for Molecular Pathology guidelines.
Key testing
Advantages
Highlights
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' test panel provides comprehensive evaluation of patients with suspected monogenic early onset inflammatory bowel disease, or IBD. Accurate diagnosis is key to guiding therapy for patients, who might be as young as 2 years of age.